Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

ABSTRACT:

Background

Adjuvant therapies are now considered standard care for high-risk melanoma patients. It is urgent to identify reliable biomarkers to select patients at high risk of relapse, who will derive more benefit from adjuvant therapy.

Methods

Targeted next-generation sequencing using a 437 cancer-related gene panel was performed on primary tumor samples from 55 patients in stage I-III melanoma and postsurgical plasma samples from 46 patients. Association analysis of clinico-genomic characteristics with disease-free survival was conducted.

Results

The median DFS was 39.2 months (rangement: 1.4-49.7 months). Patients receiving anti-PD-1 adjuvant therapy had a longer DFS than those receiving adjuvant interferon therapy (mDFS, NA vs. 21.3 months, HR 0.36 [95% CI: 0.13-1

SUBMITTER: Zhao M 

PROVIDER: S-EPMC12641966 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature